We demonstrate the potency of mildronate to normalise blood glucose against a background of STZ diabetes, suggesting that mildronate promoted the utilisation of glucose as substrate rather than affecting the plasma burden of insulin or restoring pancreatic beta-cell function, thus supporting our hypothesis. The gene discussed is INS; the disease is diabetes mellitus.